Posts

Sanofi halts eczema development of Kymab-originated OX40L antibody amlitelimab due to lack of meaningful clinical advantage and safety concerns

on

GSK's functional cure data for hepatitis B drug bepirovirsen are a major leap over standard of care

on

AbbVie’s Skyrizi yields to UCB’s Bimzelx in psoriatic arthritis head‑to‑head trial

on

ESMO 2025 KEYNOTE-671 Update: Perioperative Pembrolizumab Reinforces NSCLC Standard

on

Takeda’s Phase 3 Success Positions Oveporexton (TAK-861) as Potential First Mover in Multibillion-Dollar Narcolepsy Market

on